A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients ...
Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...
The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...
A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...
A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...
NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...
Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback